Related Experiment Video
Updated: Dec 9, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Favipiravir: A new and emerging antiviral option in COVID-19
Umang Agrawal1, Reyma Raju2, Zarir F Udwadia3
1Associate Consultant (Infectious Diseases), PD Hinduja National Hospital and Medical Research Centre, Mumbai, India.
Abstract:
With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19.
More Related Videos
Related Concept Videos
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Viruses with RNA Genomes
Retroviruses
Retrovirus Life Cycles
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

